Diagnostic accuracy of research criteria for prodromal frontotemporal dementia

Alzheimers Res Ther. 2024 Jan 12;16(1):10. doi: 10.1186/s13195-024-01383-1.

Abstract

Background: The Genetic Frontotemporal Initiative Staging Group has proposed clinical criteria for the diagnosis of prodromal frontotemporal dementia (FTD), termed mild cognitive and/or behavioral and/or motor impairment (MCBMI). The objective of the study was to validate the proposed research criteria for MCBMI-FTD in a cohort of genetically confirmed FTD cases against healthy controls.

Methods: A total of 398 participants were enrolled, 117 of whom were carriers of an FTD pathogenic variant with mild clinical symptoms, while 281 were non-carrier family members (healthy controls (HC)). A subgroup of patients underwent blood neurofilament light (NfL) levels and anterior cingulate atrophy assessment.

Results: The core clinical criteria correctly classified MCBMI vs HC with an AUC of 0.79 (p < 0.001), while the addition of either blood NfL or anterior cingulate atrophy significantly increased the AUC to 0.84 and 0.82, respectively (p < 0.001). The addition of both markers further increased the AUC to 0.90 (p < 0.001).

Conclusions: The proposed MCBMI criteria showed very good classification accuracy for identifying the prodromal stage of FTD.

Keywords: Diagnostic accuracy; Diagnostic criteria; Frontotemporal dementia; MCBMI; Prodromal.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atrophy
  • Biomarkers
  • Frontotemporal Dementia* / diagnosis
  • Frontotemporal Dementia* / genetics
  • Humans
  • Neurofilament Proteins

Substances

  • Neurofilament Proteins
  • Biomarkers